MEDTL Medical Technologies Ltd. is proud to announce a major funding milestone, having secured a €1.5 million grant from the
Cyprus Research and Innovation Foundation (RIF) and an additional €1.5 million investment from an international investment fund
through the DISRUPT program. This combined €3 million funding will empower MEDTL to scale its innovative cardiology solutions for a global market.

With this investment, MEDTL aims to advance its flagship product, AI-HEART—a sophisticated AI-powered platform that transforms raw ECG data into precise interpretations of heart conditions. “With AI-HEART, we’re setting new standards in cardiovascular diagnostics,” said Dino Matheou, founder of MEDTL. “The support from RIF is instrumental in helping us scale our solutions, paving the way for AI-HEART to become a global gold standard in cardiology. While we remain humble and focused, MEDTL is committed to executing its strategic international expansion plan. We also thank the Borghese Multi-Family Office for their guidance and support.”

MEDTL’s mission is to design, develop, and deliver cutting-edge tools that address critical needs in cardiovascular healthcare. As an innovator based in Cyprus, MEDTL continues to lead advancements in healthcare technology, empowering cardiologists worldwide with tools for accurate, data-driven diagnostics.